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In the 1990s, during the era of the
Human Genome Project, many research-
ers were very optimistic about the capacity
of such large-scale genetic projects to
revolutionize the prevention of disease
(e.g., [1,2]). Many predicted that whole
populations would be screened for their
genetic susceptibility to common diseases,
such as cancer and heart disease. Healthy
individuals who carried susceptibility al-
leles would be advised to change their
behaviour (e.g., exercise more, maintain a
healthier diet, stop smoking), or be given
drugs or other treatments to reduce their
risks of developing these diseases.
Ten years on, genome-wide association
studies (GWAS) have changed our under-
standing of the aetiology of many common
diseases such as type 1 diabetes and
obesity, but they have not identified major
susceptibility alleles for most common
diseases. With a few exceptions, suscepti-
bility alleles for the most common human
diseases have proven to be very weakly
predictive of disease risk, with odds ratios
for individual alleles typically ranging from
1.1 to 1.6 [3–5]. The susceptibility ‘‘genes’’
identified to date account for only a small
percentage of the known genetic variation
in disease risk, and the relationship between
these genetic variants and environmental
risk factors has yet to be fully investigated
[3,6].
Despite these limitations, many re-
searchers continue to advocate the use of
genetic information to predict disease risk
(e.g., [7]) and a number of private com-
panies now offer this as a service on an
individual basis. Is genetic risk prediction
feasible from a public health perspective,
in the way that many originally envisaged?
In principle, individual genetic variants
could potentially provide reasonable pre-
diction of disease risk, if the findings for
multiple susceptibility alleles were com-
bined statistically [8–12]. Modelling of this
approach has produced conflicting assess-
ments about its likely utility (e.g., [13–16]).
The same has been true of empirical
tests of genetic prediction of common
complex traits (see [17] for a list of recent
studies).
In many contexts, information from
multiple genetic variants does not appear
to provide better prediction than known
risk factors such as family history or
environmental risks. For instance, Lango
and colleagues [18] found that 18 genetic
variants that individually predicted an
increased risk of diabetes were not able
to discriminate between type 2 diabetes
cases and controls and only marginally
improved upon predictions using age,
body mass index (BMI), and sex. Studies
of genomic prediction of coronary heart
disease and cardiovascular events have
also found that genotypic information is
less predictive of disease risk than are age,
blood pressure, cholesterol, triglycerides,
cigarette use, and diabetes [19,20]. On the
other hand, there are some cases in which
genotypic information discriminates be-
tween subpopulations that differ markedly
in disease risk. For instance, Pharoah and
colleagues [21] found that combinations of
breast cancer susceptibility alleles discrim-
inated between women at low and high
risk of breast cancer on the basis of family
history.
The difference in success of prediction
between these empirical studies is perhaps
not surprising; disease prevalence and
heritability are important determinants of
the clinical utility of a genetic test. Also,
genetic associations often vary by popula-
tion, because population level variations in
location, ethnicity, age, and other factors
influence the prevalence not only of
genetic risk factors for common diseases,
but also of environmental and behavioural
risk factors for common diseases, such as
tobacco and alcohol use, diet, and exercise
[22]. Consequently, the predictive capac-
ity and clinical utility of genetic tests will
depend upon the population in which they
are used and the disease(s) for which risk is
being predicted. Thus it is not possible to
make any overarching statement about the
utility of predictive genetic tests. We can,
however, outline some of the likely con-
straints on the implementation of popula-
tion-wide screening using genetic tests to
predict disease risk.
Constraints on Public Health
Impact
Cost-Effectiveness of Predictive
Genomic Medicine
Advocates of the preventive use of
genetic risk information often simply
assume that preventive interventions will
be cost-effective if genotypic information
can be shown to predict disease risk (e.g.
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[7]). From a public health perspective,
however, population-wide screening (ge-
netic or otherwise) is ethically justifiable
only if there is an efficacious and cost-
effective intervention to prevent the disor-
der in those who are identified as being at
increased risk [23–25]. For common
cancers, such as colorectal and breast
cancer, regular monitoring and early
treatment can reduce mortality, and there
are also preventive medications for hyper-
cholesterolemia and high blood pressure.
However, even if efficacious interven-
tions are available, we need large con-
trolled trials to assess whether providing
these interventions to asymptomatic indi-
viduals at increased genetic risk is more
cost-effective than treating all persons
displaying physiological risk factors (such
as elevated blood pressure or cholesterol)
[26,27]. Prostate-specific antigen (PSA)
screening provides a cautionary example.
A positive PSA test is modestly predictive
of the risk of developing invasive cancer of
the prostate [28] but epidemiological
modelling shows that 1,500 men need to
be screened to prevent one death from
prostate cancer and this death would be
averted at the cost of unnecessary surgery
for 80 low-risk men whose quality of life
would be seriously impaired [29].
Behavioural Impacts of Genetic Risk
Information
Some advocates of genomic medicine
simply assume that giving genetic risk
information will prompt individuals to
change their behaviour in desired direc-
tions [26,30]. It is not clear that this is the
case [8,31]. Information about genetic
susceptibility to disease only seems to
have, at most, a small negative psycholog-
ical impact on result recipients ([32–34]),
but inappropriate communication of ge-
netic risk information may actually under-
mine individuals’ beliefs about their ability
to change their behaviour [35,36].
There is some evidence that genetic risk
information may make individuals assume
that prevention requires pharmacological
intervention [37]. For example, genetic
risk information about familial hypercho-
lesterolaemia [35] increased individuals’
beliefs that the best way to reduce their
risk was to use lipid-lowering medication
rather than to change their diet or increase
exercise. Wright et al. [36] found that
smokers who were told that they had a
genetic predisposition to nicotine depen-
dence were more likely to believe that they
needed to use a drug to quit smoking,
despite the fact that most smokers quit
unaided [38].
It is also unclear whether genetic risk
information produces sustained changes in
risk behaviour [34]. Studies have shown
that testing positively for a genetic predis-
position to lung cancer increased smoking
cessation attempts [39] and reduced the
number of cigarettes smoked [40] but
neither of these changes lasted for more
than six months. Another study reported
genetic testing for hereditary breast and
ovarian cancer promoted healthy lifestyle
changes in approximately half of all
patients tested, but behaviour change did
not differ between carriers and non-
carriers of the gene [41].
Competing Population Health
Strategies
Predictive genomic medicine adopts a
‘‘high risk’’ strategy [25] that targets
interventions at individuals who are at
the highest risk of developing a disease [9].
Public health professionals are concerned
that an uncritical embrace of ‘‘high
risk’’ strategies will displace more effective
strategies that aim to shift population
distributions of risk exposures, for example
by reducing the population prevalence of
cigarette smoking, per capita alcohol
consumption, average blood pressure, or
the consumption of energy-dense foods
[25].
Population-based tobacco control strat-
egies, such as taxing cigarettes and reduc-
ing opportunities to smoke, have halved
cigarette smoking rates in Australia [42]
and the US [43] over the past three
decades. These population-based strate-
gies are more efficient than high-risk
strategies [25] because fewer resources
are needed to increase taxes on tobacco
products, ban cigarette advertising, and
restrict opportunities to smoke than are
needed to screen whole populations in
order to identify and intervene with the
minority at high genetic risk of becoming
nicotine dependent or developing tobacco-
related diseases, if they smoke tobacco
[9,44].
There are similar arguments for the
greater efficiency of population-based
strategies in reducing risky alcohol use,
obesity, and diabetes. These strategies aim
to reduce population access to cheap
energy-dense foods and increase opportu-
nities to exercise. Based on the successful
experiences in tobacco control, such
strategies will probably include: increased
taxes on, reductions in the promotion of,
and decreased availability of, energy-dense
foods; and redesigning urban environ-
ments to reduce sedentary behaviour and
increase opportunities for incidental exer-
cise in everyday life [45,46].
Subversive Uses of Genomic Risk
Information
Public health professionals are also
concerned about the potential misuse of
genetic risk information by industries that
wish to promote harmful forms of con-
sumption (tobacco, alcohol, energy dense
foods, and gambling). These industries are
likely to advocate for population-wide
genetic screening in order to undermine
public health policies that will reduce the
use of their products in the population
[47].
Analyses of industry documents [48]
demonstrate that this is why the tobacco
industry funded behavioural and molecu-
lar genetic research on smoking and
tobacco-related disease in the 1970s and
1980s. A strategic decision was taken to
promote genetic explanations of tobacco-
related disease (initially promoted by the
geneticist R.A. Fisher). By locating the
risks of smoking in the genome of the
individual smokers, this research could be
used to exonerate tobacco smoking as a
cause of disease [48].
The alcohol industry has also promoted
the idea that alcohol-related problems
only occur in a minority of genetically
vulnerable drinkers [49]. The policy
implication favoured by the industry is
that alcohol problems are better addressed
by identifying and intervening with prob-
lem drinkers rather than adopting effective
strategies for reducing population-level
alcohol consumption, such as increased
Summary Points
Before genomic information is used in public health screening, it must be shown
that:
N such information predicts disease risk better than phenotypic information;
N cost-effective interventions exist for those at increased genetic risk;
N these interventions are more cost-effective than population-level interventions;
N genetic risk information motivates desired behaviour change.
Currently there are no examples of genetic screening for disease risk that satisfy
these criteria.
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taxation and reduced availability of alco-
hol [50]. The gambling industry has
recently funded research into the genetics
and neurobiology of problem gambling
[51] for presumably similar strategic
reasons. The food industries will find
genetic explanations of obesity similarly
useful in undermining population-wide
strategies to reduce obesity by modifying
obesogenic environments [46].
The Necessity for Technology
Evaluation
The major public health challenge in
formulating a policy toward population-
wide genomic screening will be in discov-
ering how to obtain whatever public
health benefits genomic medicine delivers
for common diseases without undermining
effective population health policies that
reduce exposure to the common risk
factors responsible for the high prevalence
of these diseases in developed countries
[9].
Public health utility should, however, be
differentiated from the usefulness of ge-
netic information in a medical context.
Research may identify low-frequency ge-
netic variants with large effects that can be
used in matching treatments to patients in
clinical settings. Rare variants may also
identify promising new targets for drugs to
treat common diseases. But the usefulness
of such variants for public health screening
will be limited because of their low
frequency in the population.
Although early research has not shown
a strong improvement in predictive power
when genetic and environmental factors
are combined to estimate disease risk, the
use of Mendelian randomisation may
enable epidemiologists to assess the causal
role of environmental factors in common
diseases [52]. If the relationship between
genetic and environmental risk factors can
be better characterised, the utility of public
health screening tests may be improved by
combining phenotypic and environmental
information and administering such tests
to subsets of the population who have
other indicators of increased risk (such as a
history of early-onset disease in first-degree
relatives).
But it is clear that genetic screening of
whole populations is unlikely to transform
preventive health in the ways predicted 10
years ago. The integration of individual
genomic risk prediction into public health
disease prevention strategies will require
good evidence that this approach im-
proves on the cost-effectiveness of existing
population level interventions. The utility
and cost-effectiveness of predictive geno-
mics, like any other new health technolo-
gy, should be evaluated disease-by-disease
and population-by-population. Its utility
will depend not only upon the costs of
genetic screening (which have fallen rap-
idly) but also on: the effectiveness of
treating those at increased risk; the
morbidity and mortality that these pre-
ventive interventions avert and cause; and
on our ability to prevent the subversive use
of genomic information by interested
industries to undermine effective public
health policies. Until we have a much
stronger evidence base, and more data on
interactions between genotypes and com-
mon environmental exposures, advocates
of genomic medicine should be much
more modest than some have been in the
claims they make about its likely impacts
upon population health.
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